Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

Collection:
Health Policy and Services Research
Author(s):
Whittington, Melanie D., author
Campbell, Jonathan D., author
Richardson, Marina, author
Nhan, Emily, author
McKenna, Avery, author
Agboola, Foluso, author
Pearson, Steven D., author
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, December 20, 2022
Language(s):
English
Format:
Text
Subject(s):
Ambulatory Care -- economics
Antiviral Agents -- economics
COVID-19 Drug Treatment
Drug Combinations
Drug Costs
Lactams
Leucine
Nitriles
Proline
Ritonavir
United States
Genre(s):
Technical Report
Abstract:
In May 2022, the Institute for Clinical and Economic Review (ICER) published a special assessment of several emerging outpatient treatment options for COVID-19. Since that time, the drug nirmatrelvir/ritonavir (Paxlovid, Pfizer) has become the leading treatment option. In addition, since May 2022, the viral epidemiology of COVID-19 has continued to evolve, increasing numbers of Americans have either been vaccinated and/or gained increased immunity from prior infections, and further evidence has been published on the relative effectiveness of treatment. It is also anticipated that in early-mid 2023 the payment for Paxlovid for many patients will begin to shift from prior federal contracts over to new pricing and payment arrangements negotiated between Pfizer and commercial insurers. Although dominant viral variants, vaccination/prior infection status, and evidence on Paxlovid will continue to evolve, and some questions, such as the relative impact on long COVID are still highly uncertain, we are presenting an update to our calculations of a health-benefit price benchmark range for Paxlovid at this time to help inform new discussions on fair pricing for the dominant outpatient treatment option for COVID-19.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (i, 3 pages))
NLM Unique ID:
9918697386606676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918697386606676